Cardinal Systems

PureTech expands scientific advisory board team and advisory group

Friday, July 8, 2016

PureTech Health, a cross-disciplinary biotech company developing novel medicines at the interface of the gut, brain and immune system, has announced the appointment of Feng Zhang, Ph.D., to its scientific advisory board (SAB). The company has also appointed Jeff Stevens, as vice president of Growth Strategy & Operations and has expanded its team of senior advisors to include Meghan Fitzgerald, DrPH, executive vice president of Corporate Strategy, M&A and Health Policy at Cardinal Health; Atul Pande, M.D., former senior vice president and head of Neurosciences at GlaxoSmithKline; and Philip J. Larsen, M.D., Ph.D., global head of Diabetes Research & Development at Sanofi.

[Read More]

Valeant names Joseph C. Papa chairman, CEO

Tuesday, April 26, 2016

Valeant Pharmaceuticals International has named Joseph C. Papa to become Valeant’s chairman and chief executive officer. Papa is expected to join Valeant by early May. Papa will join Valeant from Perrigo company, a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as chairman and chief executive officer. Papa, who will also join Valeant’s board of directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a director until Papa arrives at Valeant.

[Read More]

Cardinal Health to acquire Johnson & Johnson’s Cordis

Wednesday, March 4, 2015

Johnson & Johnson has received a binding offer from Cardinal Health, a healthcare services company based in Dublin, Ohio, to acquire its Cordis business for an aggregate value of $1.99 billion, consisting of $1.944 billion of cash proceeds from Cardinal Health plus approximately $46 million of retained net receivables. Cordis is a developer and manufacturer of interventional vascular technology with 2014 net revenues of approximately $780 million.

[Read More]